Taysha Gene Therapies (NASDAQ:TSHA) Coverage Initiated by Analysts at BMO Capital Markets

BMO Capital Markets started coverage on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report released on Thursday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $5.00 price target on the stock.

TSHA has been the subject of several other research reports. Piper Sandler assumed coverage on shares of Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an overweight rating and a $9.00 price target for the company. JMP Securities reiterated a market outperform rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Chardan Capital reiterated a buy rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, June 18th. Jefferies Financial Group reiterated a buy rating and issued a $8.00 price objective (up from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday, May 14th. Finally, Cantor Fitzgerald reiterated an overweight rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and an average price target of $6.80.

Taysha Gene Therapies Price Performance

TSHA stock opened at $2.24 on Thursday. The firm has a market cap of $418.92 million, a price-to-earnings ratio of -4.57 and a beta of 0.50. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.75. Taysha Gene Therapies has a 12-month low of $0.58 and a 12-month high of $4.32. The company’s fifty day simple moving average is $2.97 and its 200 day simple moving average is $2.42.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The company had revenue of $3.41 million for the quarter, compared to analysts’ expectations of $3.70 million. During the same quarter in the prior year, the firm earned ($0.28) EPS. On average, analysts expect that Taysha Gene Therapies will post -0.43 earnings per share for the current year.

Institutional Trading of Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently modified their holdings of TSHA. FMR LLC increased its position in Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company’s stock valued at $77,508,000 after purchasing an additional 23,378,974 shares during the period. RA Capital Management L.P. purchased a new position in Taysha Gene Therapies during the 3rd quarter valued at about $58,373,000. RTW Investments LP purchased a new position in Taysha Gene Therapies during the 3rd quarter valued at about $53,382,000. Avoro Capital Advisors LLC grew its position in shares of Taysha Gene Therapies by 328.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock worth $53,526,000 after buying an additional 14,294,445 shares during the last quarter. Finally, Acuta Capital Partners LLC purchased a new position in shares of Taysha Gene Therapies in the 3rd quarter worth approximately $12,096,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.